Here are four points:
1. Dr. Scharschmidt most recently served as senior vice president and chief medical and development officer at Hyperion Therapeutics, which was acquired by Horizon Pharma in 2015.
2. Board-certified in internal medicine and gastroenterology, he has previously served as chief of gastroenterology at University of California, San Francisco, helping launch the UCSF liver transplant program.
3. He has also previously served as an associate editor of Gastroenterology and editor-in-chief of the Journal of Clinical Investigation.
4. Umecrine Cognition, a Swedish company, primarily focuses on developing a treatment for overt hepatic encephalopathy.
More articles on GI/endoscopy:
EndoGastric Solutions receives medical coverage for TIF procedure with EsophyX device, Takeda & Altos partner to develop gastroparesis treatment & more — 4 GI company key notes
AGA, Pfizer offer new IBD-related research grants: 4 notes
UCLA researchers identify risk factors for tainted scopes’ bacteria transmission — 5 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.